Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Lymphoma, Large B-Cell, Diffuse

Lymphoma, B-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

Lymphosarcoma

B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

Antineoplastic Agents

All Drugs and Chemicals

Antirheumatic Agents

Gemcitabine

Obinutuzumab

Rituximab

Oxaliplatin

Antimetabolites

Antineoplastic Agents, Immunological

Participants will receive up to 8 cycles of glofitamab (Glofit) in combination with gemcitabine and oxaliplatin (GemOx), followed by up to 4 cycles of glofitamab monotherapy. A single dose of obinutuzumab will be administered 7 days prior to the first dose of glofitamab. Treatment is administered in 21-day cycles.

Participants will receive rituxumab (R) in combination with gemcitabine and oxaliplatin (GemOx) for up to 8 cycles. Treatment is administered in 21-day cycles.

Participants will receive a single dose of intravenous (IV) obinutuzumab pre-treatment 7 days prior to the first dose of glofitamab.

Participants will receive IV glofitamab for up to 12 cycles.

Glofitamab

Participants will receive IV rituxumab on Day 1 of each cycle for up to 8 cycles.

Rituxumab

Participants will receive IV tocilizumab as needed for treatment of cytokine-release syndrome (CRS).

Tocilizumab

Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.

Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.

Clinical Trials

This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (Glofit-GemOx) compared with rituximab in combination with gemcitabine plus oxaliplatin (R-GemOx) in patients with R/R DLBCL.

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Hoffmann-La Roche

Anti-Inflammatory Agents

Anti-Infective Agents

Cyclophosphamide

Doxorubicin

Liposomal doxorubicin

Prednisone

Vincristine

Polatuzumab vedotin

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Tubulin Modulators

Antimitotic Agents

Immunoconjugates

Participants will receive M-CHOP up to the phase II recommended dose (RP2D).

Participants will receive M-CHP-Pola up to the RP2D.

Participants with 1L DLBCL will receive mosunetuzumab at the RP2D in combination with CHOP.

Participants with 1L DLBCL will receive M-CHP-Pola at a dose determined in the dose finding stage.

Participants with 1L DLBCL will receive R-CHP-Pola at a dose determined in the dose finding stage.

Participants with 1L DLBCL will receive M-CHOP at a dose determined in the dose finding stage.

Participants will receive intravenous (IV) mosunetuzumab.

Mosunetuzumab

Participants will receive polatuzumab vedotin via IV.

Polatuzumab Vedotin

Participants will receive rituxumab via IV.

Participants will receive cyclophosphamide via IV.

Participants will receive doxorubicin via IV.

Participants will receive vincristine via IV.

Participants will receive oral prednisone.

Participants will receive tocilizumab via IV.

This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (M-CHOP) and, subsequently, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) plus polatuzumab vedotin (CHP-pola) in participants with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL), and in previously untreated participants with diffuse large B-cell lymphoma (DLBCL).

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	NCT04408638	Diffuse Large B...	Obinutuzumab Glofitamab Rituxumab Tocilizumab Gemcitabine Oxaliplatin	18 Years -	Hoffmann-La Roche
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma	NCT03677141	B-cell Non-Hodg...	Mosunetuzumab Polatuzumab Ved... Rituxumab Cyclophosphamid... Doxorubicin Vincristine Prednisone Tocilizumab	18 Years -	Hoffmann-La Roche
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	NCT04408638	Diffuse Large B...	Obinutuzumab Glofitamab Rituxumab Tocilizumab Gemcitabine Oxaliplatin	18 Years -	Hoffmann-La Roche
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	NCT04408638	Diffuse Large B...	Obinutuzumab Glofitamab Rituxumab Tocilizumab Gemcitabine Oxaliplatin	18 Years -	Hoffmann-La Roche

Spots Global Cancer Trial Database for rituxumab

Every month we try and update this database with for rituxumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for rituxumab

Every month we try and update this database with for rituxumab cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for rituxumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.